Serotonin neurotoxins - Past and present

Neurotoxicity Research

Volumn 6, Issue 7-8, 2004, Pages 589-614

  Baumgarten, H G ^a   Lachenmayer, L ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ASKLEPIOS HOSPITAL BARMBEK   (Germany)

Author keywords

5,6 Dihydroxytryptamine; 5,7 Dihydroxytryptamine; 6 Hydroxydopamine; Astroglia; Autoxidation pathways; Dopaminergic neurons; Free radical toxicity; Hyperthermia; Metabolism; Microglia; Oxidative stress; Pharmacokinetics; Serotonergic neurons; Substituted amphetamines; Transcriptional effects

Indexed keywords

DRUG DERIVATIVE; NEUROTOXIN; SEROTONIN;

ANIMAL; DRUG EFFECT; HUMAN; METABOLISM; NERVE CELL; REVIEW;

ANIMALS; HUMANS; NEURONS; NEUROTOXINS; SEROTONIN;

EID: 15844376730     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033455     Document Type: Article

References (179)

1. Acarin L, B Gonzalez and B Castellano (2000) Neuronal, astroglial and microglial cytokine expression after an excitotoxic lesion in the immature rat brain. Eur. J. Neurosci. 12, 3505-3520.
2. Albers DS and MF Beal (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm. Suppl. 59, 133-154. Review.
3. Asanuma M, T Tsuji, I Miyazaki, K Miyoshi and N Ogawa (2003) Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci. Lett. 352, 13-16.
4. Axt KJ, LA Mamounas and ME Molliver (1994) Structural features of amphetamine neurotoxicity in the brain, In: Amphetamine and its Analogs (Cho AK and DS Segal, Eds.) (Academic Press: San Diego, New York), pp 315-367.
5. Bai F, DC Jones, SS Lau and TJ Monks (2001) Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/ -)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase. Chem. Res. Toxicol. 14, 863-870.
6. Bai F, SS Lau and TJ Monks (1999) Glutathione and N-acetylcysteine conjugates of ?-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetaminemediated neurotoxicity. Chem. Res. Toxicol. 12, 1150-1157.
7. Bal-Price A and GC Brown (2001) Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 21, 6480-6491.
8. Battaglia G, SY Yeh, E O'Hearn, ME Molliver, MJ Kuhar and EB De Souza (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3 H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242, 911-916.
9. Battaglia G, SY Yeh and EB De Souza (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29, 269-274.
10. Battaglia G, F Fornai, CL Busceti, G Aloisi, F Cerrito, A De Blasi, D Melchiorri and F Nicoletti (2002) Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci. 22, 2135-2141.
11. Baumgarten HG and A Björklund (1976) Neurotoxic indoleamines and monoamine neurons. Annu. Rev. Pharmacol Toxicol. 16, 101-111. Review.
12. Baumgarten HG and Z Grozdanovic (2000) 6-Hydroxydopamine, In: Experimental and Clinical Neurotoxicology, 2nd Edition, (Spencer P, HH Schaumburg and AC Ludolph, Eds.) (Oxford University Press: Oxford, New York), pp 659-667.
13. Baumgarten HG and B Zimmermann (1992) Neurotoxic phenylalkylamines and indolealkylamines, In: Selective Neurotoxicity (Herken H and F Hucho, Eds.) (Springer-Verlag: Berlin, Heidelberg, New York). Handbook Exp. Pharmacol. 102, pp 225-291.
14. Baumgarten HG, A Björklund, L Lachenmayer, A Nobin and U Stenevi (1971) Long-lasting selective depletion of brain serotonin by 5,6-dihydroxytryptamine. Acta Physiol. Scand. Suppl. 373, 1-15.
15. Baumgarten HG, A Björklund, L Lachenmayer and A Nobin (1973) Evaluation of the effects of 5,7-dihydroxytryptamine on serotonin and catecholamine neurons in the rat CNS. Acta Physiol. Scand. Suppl. 391, 1-19.
16. Baumgarten HG, A Björklund, L Lachenmayer, A Rensch and E Rosengren (1974) De- and regeneration of the bulbospinal serotonin neurons in the rat following 5,6- or 5,7-dihydroxytryptamine treatment. Cell Tissue Res. 152: 271-281.
17. Baumgarten HG, A Björklund, A Nobin, E Rosengren and HG Schlossberger (1975) Neurotoxicity of hydroxylated tryptamines: structure-activity relationships. 1. Long-term effects on monoamine content and fluorescence morphology of central monoamine neurons. Acta Physiol. Scand. Suppl. 429, 5-27.
18. Baumgarten HG, L Lachenmayer and A Björklund (1977) Chemical lesioning of indoleamine pathwys, In: Methods in Psychobiology, Vol. III (Myers RD, Ed.) (Academic Press: London, Nw York), pp 47-98.
19. Baumgarten HG, HP Klemm, J Sievers and HG Schlossberger (1982) Dihydroxytryptamines as tools to study the neurobiology of serotonin. Brain Res. Bull. 9, 131-150.
20. Bergami A, C Fracasso, S Garattini and S Caccia (1995) Brain uptake and acute indole-depleting effect of dexfenfluramine in squirrel monkeys after a high-dose regime. Pharmaceut. Sci. 1, 45-48.
21. Birmes P, D Coppin, L Schmitt and D Lauque (2003) Serotonin syndrome: abrief review. CMAJ 168, 1439-1442. Review.
22. Björklund A and L Wiklund (1980) Mechanisms of regrowth of the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. I. Biochemical correlates. Brain Res. 191, 109-127.
23. Björklund A, HG Baumgarten and A Rensch (1975a) 5,7-Dihydroxytryptamine: Improvement of its selectivity for serotonin neurons in the CNS by pretreatment with desipramine. J. Neurochem. 24, 833-835.
24. Björklund A, AS Horn, HG Baumgarten, A Nobin and HG Schlossberger (1975b) Neurotoxicity of hydroxylated tryptamines: Structure-activity relationships. 2. In vitro studies on monoamine uptake inhibition and uptake impairment. Acta Physiol. Scand. Suppl. 429, 29-60.
25. Blank CL, RJ Lewis and RE Lehr (1998) 6-Hydroxydopamine and related catecholaminergic neurotoxins, In: Highly Selective Neurotoxins (Kostrzewa RM, Ed.) (Humana Press: Totowa, NJ), pp 1-18.
26. Bolton JL, MA Trush, TM Penning, G Dryhurst and TJ Monks (2000) Role of quinones in toxicology. Chem. Res. Toxicol. 13, 135-160. Review.
27. Bowyer JF, JF Young, W Slikker Jr, Y Itzak, AJ Mayorga, GD Newport, SF Ali, DL Frederick and MG Paule (2003) Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24, 379-390.
28. Brown JM and BK Yamamoto (2003) Effects of amphetamines on mitochondrial function: Role of free radicals and oxidative stress. Pharmacol. Ther. 99, 45-53. Review
29. Brown PL and EA Kiyatkin (2004) Brain hyperthermia induced by MDMA ('ecstasy'): Modulation by environmental conditions. Eur. J. Neurosci. 20, 51-58.
30. Bruno V, I Ksiazek, G Battaglia, S Lukic, T Leonhardt, D Sauer, F Gasparini, R Kuhn, F Nicoletti and PJ Flor (2000) Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 39, 2223-2230.
31. Buchert R, R Thomasius, F Wilke, K Petersen, B Nebeling, J Obrocki, O Schulze, U Schmidt and M Clausen (2004) A Voxelbased PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am. J. Psychiatry 161, 1181-1189.
32. Burrows KB, G Gudelsky and BK Yamamoto (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur. J. Pharmacol. 398, 11-18.
33. Caccia S, M Ballabio, G Guiso, M Rocchetti and S Garattini (1982) Species differences in the kinetics and metabolism of fenfluramine isomers. Arch. Int. Pharmacodyn. Ther. 258, 15-28.
34. Caccia S, A Bergami, C Fracasso, S Garattini and B Campbell (1995) Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates. Xenobiotica 25, 1143-1150.
35. Caccia S, S Confalonieri, A Bergami, C Fracasso, M Anelli and S Garattini (1997) Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: A comparison with fluoxetine. Pharmacol. Biochem. Behav. 57, 851-856.
36. Cadet JL, B Ladenheim, I Baum, E Carlson and C Epstein (1994) CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res. 655, 259-262.
37. Cadet JL, S Jayanthi, MT McCoy, M Vawter and B Ladenheim (2001) Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: Evidence from cDNA array. Synapse 41, 40-48.
38. Cadet JL, MT McCoy and B Ladenheim (2002) Distinct gene expression signatures in the striata of wild-type and heterozygous c-fos knockout mice following methamphetamine administration: Evidence from cDNA array analyses. Synapse 44, 211-226.
39. Cadet JL, S Jayanthi and X Deng (2003) Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J. 17, 1775-1788. Review.
40. Camarero J, V Sanchez, E O'Shea, AR Green and MI Colado (2002) Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J. Neurochem. 81, 961-972.
41. Campbell DB, RP Richards, S Caccia and S Garattini (1986) Stereo-selective metabolism and the fate of fenfluramine in animals and man., In: Development of Drug and Modern Medicines (Gorrod JW, GC Gibson and M Mitchard, Eds.) (Horwood: Chichester, UK), pp 298-311.
42. Cappon GD, C Pu and CV Vorhees (2000) Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment. Brain Res. 863, 106-111.
43. Carvalho M, F Remiao, N Milhazes, F Borges, E Fernandes, C Monteiro Mdo, MJ Goncalves, V Seabra, F Amado, F Carvalho and ML Bastos (2004a) Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem. Res. Toxicol. 17, 623-632.
44. Carvalho M, F Remiao, N Milhazes, F Borges, E Fernandes, F Carvalho and ML Bastos (2004 b) The toxicity of N -methyl-α-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N -acetylcysteine. Toxicology 200, 193-203.
45. Carvalho M, N Milhazes, F Remiao, F Borges, E Fernandes, F Amado, TJ Monks, F Carvalho and ML Bastos (2004c) Hepatotoxicity of 3,4-methylenedioxyamphetamine and α-methyldopamine in isolated rat hepatocytes: Formation of glutathione conjugates. Arch. Toxicol. 78, 16-24.
46. Cheymol G, J Weissenburger, JM Poirier and C Gellee (1995) The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br. J. Clin. Pharmacol. 39, 684-687.
47. Cho AK and Y Kumagai (1994) Metabolism of amphetamine and other arylisopropylamines, In: Amphetamines and its Analogs (Cho AK and DS Segal, Eds.) (Academic Press, San Diego, New York), pp 43-77.
48. Cho AK, WP Melega, R Kuczenski and DS Segal (2001) Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39, 161-166. Review.
49. Cho T, Y Kumagai, EW DiStefano and AK Cho (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem. Pharmacol. 51, 789-796.
50. Choi S, E Jonak and JD Fernstrom (2004) Serotonin reuptake inhibitors do not prevent 5,7-dihydroxytryptamine-induced depletion of serotonin in rat brain. Brain Res. 1007, 19-28.
51. Christensen JD, DA Yurgelun-Todd, SM Babb, SA Gruber, BM Cohen and PF Renshaw (1999) Measurement of human brain dexfenfluramine concentration by 19 F magnetic resonance spectroscopy. Brain Res. 834, 1-5.
52. Clausing P, GD Newport and JF Bowyer (1998) Fenfluramine and norfenfluramine levels in brain microdialysate, brain tissue and plasma of rats administered doses of d-fenfluramine known to deplete 5-hydroxytryptamine levels in brain. J. Pharmacol. Exp. Ther. 284, 618-624.
53. Colado MI, E O'Shea, R Granados, TK Murray and AR Green (1997) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol. 121, 889-900.
54. Colado MI, E O'Shea, R Granados, B Esteban, AB Martin and AR Green (1999) Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. Br. J. Pharmacol. 126, 911-924.
55. Colado MI, J Camarero, AO Mechan, V Sanchez, B Esteban, JM Elliott and AR Green (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethampheta mine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br. J. Pharmacol. 134, 1711-1723.
56. Commins DL, KJ Axt, G Vosmer and LS Seiden (1987a) 5,6-Dihydroxytryptamine, a serotonergic neurotoxin, is formed endogenously in the rat brain. Brain Res. 403, 7-14.
57. Commins DL, KJ Axt, G Vosmer and LS Seiden (1987b) Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine. Brain Res. 419, 253-261.
58. de la Torre R and M Farre M (2004) Neurotoxicity of MDMA (ecstasy): The limitations of scaling from animals to humans. Trends Pharmacol. Sci. 25 (10), 505-508.
59. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J and J Cami (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol. 49, 104-109.
60. de la Torre R, M Farre, PN Roset, N Pizarro, S Abanades, M Segura, J Segura and J Cami (2004) Human pharmacology of MDMA, pharmacokinetics, metabolism, and disposition. Ther. DrugMonit. 26, 137-144.
61. de Souza EB, G Battaglia and TR Insel (1990) Neurotoxic effect of MDMA on brain serotonin neurons, evidence from neurochemical and radioligand binding studies. Ann. NYAcad. Sci. 600, 682-698. Review.
62. Deng X and JL Cadet (1999) Methamphetamine administration causes overexpression of nNOS in the mouse striatum. Brain Res. 851, 254-257.
63. Deng X, B Ladenheim, LI Tsao and JL Cadet (1999) Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J. Neurosci. 19, 10107-10115.
64. Deng X, NS Cai, MT McCoy, W Chen, MA Trush and JL Cadet (2002) Methamphetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology 42, 837-845.
65. Easton N, J Fry, E O'Shea, A Watkins, S Kingston and CA Marsden (2003) Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of α-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res. 987, 144-154.
66. Ener RA, SB Meglathery, WA Van Decker and RM Gallagher (2003) Serotonin syndrome and other serotonergic disorders. Pain Med. 4, 63-74. Review.
67. Farfel GM, GL Vosmer and LS Seiden (1992) The N -methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylene-dioxymethamphetamine and p-chloroamphetamine. Brain Res. 595, 121-127.
68. Farre M, R de la Torre, BO Mathuna, PN Roset, AM Peiro, M Torrens, J Ortuno, M Pujadas and J Cami (2004) Repeated doses administration of MDMA in humans, pharmacological effects and pharmacokinetics. Psychopharmacology (Berl.) 173, 364-375.
69. Fischer C, G Hatzidimitriou, J Wlos, J Katz and G Ricaurte (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylene-dioxymethamphetamine (MDMA, "ecstasy"). J. Neurosci. 15, 5476-5485.
70. Fornai F, P Lenzi, M Gesi, P Soldani, M Ferrucci, G Lazzeri, L Capobianco, G Battaglia, A De Blasi, F Nicoletti and A Paparelli (2004a) Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC 12 cells. J. Neurochem. 88(1), 114-123.
71. Fornai F, P Lenzi, G Frenzilli, M Gesi, M Ferrucci, G Lazzeri, F Biagioni, M Nigro, A Falleni, M Giusiani, A Pellegrini, F Blandini, S Ruggieri and A Paparelli (2004b) DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). Psychopharmacology (Berl.) 173, 353-363.
72. Fritschy JM and R Grzanna (1989) Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience 30, 181-197.
73. Fritschy JM and R Grzanna (1992) Degeneration of rat locus coeruleus neurons is not accompanied by an irreversible loss of ascending projections. Evidence for reestablishment of forebrain innervation by surviving neurons. Ann. NYAcad. Sci. 648, 275-278.
74. Fukumura M, GD Cappon, C Pu, HW Broening and CV Vorhees (1998) A single dose model of methamphetamine-induced neurotoxicity in rats: Effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 806, 1-7.
75. Fuller RW and MG Henderson (1994) Neurochemistry of halogenated amphetamines, In: Amphetamines and its Analogs (Cho AK and DS Segal, Eds.) (Academic Press: San Diego, New York), pp 209-242.
76. Gal EM and AD Sherman (1978) Cerebral metabolism of some serotonin depletors. Ann. NYAcad. Sci. 305, 119-127.
77. Gao HM, B Liu B, W Zhang and JS Hong (2003) Novel antiinflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24, 395-401. Review.
78. Garattini S and S Caccia (1979) Comparison of the plasma levels of fenfluramine in rats after a toxic dose and in man after a maximal therapeutic dose. Toxicol. Lett. 3, 285-290.
79. Garattini S and S Caccia (1990) Significance of fenfluramine neurotoxicity, a kinetic approach, In: Serotonin-from Cell Biology to Pharmacology and Therapeutics (Paoletti R, PM Vanhoutte, M Brunello and FM Maggi, Eds.) (Kluwer: Dordrecht), pp 637-643.
80. Garside S and PI Rosebush (2003) Serotonin syndrome, not a benign toxidrome. CMAJ 169, 543.
81. Gluck MR, LY Moy, E Jayatilleke, KA Hogan, L Manzino and PK Sonsalla (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem. 79, 152-60.
82. Green AR, E O'Shea and MI Colado (2004) A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur. J. Pharmacol. 500, 3-13.
83. Guilarte TR, MK Nihei, JL McGlothan and AS Howard (2003) Methamphetamine-induced deficits of brain monoaminergic neuronal markers, distal axotomy or neuronal plasticity. Neuroscience 122, 499-513.
84. Hickey MJ, KA Sharkey, EG Sihota, PH Reinhardt, JD Macmicking, C Nathan and P Kubes (1997) Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J. 11, 955-964.
85. Itzhak Y, C Gandia, PL Huang and SF Ali (1998) Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamineinduced dopaminergic neurotoxicity. J. Pharmacol. Exp. Ther. 284, 1040-1047.
86. Itzhak Y, JL Martin and SF Ali (1999) Methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice. Synapse 34, 305-312.
87. Itzhak Y, SF Ali and KL Anderson (2003) Fenfluramine-induced serotonergic neurotoxicity in mice, lack of neuroprotection by inhibition/ablation of nNOS. J. Neurochem. 87, 268-271.
88. Jacoby JA and LD Lytle (1978) Serotonin Neurotoxins. Ann. NY Acad. Sci. 305.
89. Jakab RL and JF Bowyer (2002) Parvalbumin neuron circuits and microglia in three dopamine-poor cortical regions remain sensitive to amphetamine exposure in the absence of hyperthermia, seizure and stroke. Brain Res. 958, 52-69.
90. Jayanthi S, X Deng, M Bordelon, MT McCoy and JL Cadet (2001) Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex. FASEB J 15, 1745-1752.
91. Jayanthi S, X Deng, PA Noailles, B Ladenheim and JL Cadet (2004) Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J 18, 238-251.
92. Jekabsone A, L Ivanoviene, GC Brown and V Borutaite (2003) Nitric oxide and calcium together inactivate mitochondrial complex I and induce cytochrome c release. J. Mol. Cell. Cardiol. 35, 803-809.
93. Johnson EA, AA Shvedova, E Kisin, JP O'Callaghan, C Kommineni and DB Miller (2002) d-MDMA during vitamin E deficiency, effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res. 933, 150-163.
94. Johnson EA, JP O'Callaghan and DB Miller (2004) Brain concentrations of d-MDMA are increased after stress. Psychopharmacology (Berl.) 173, 278-286.
95. Jones DC, SS Lau and TJ Monks (2004) Thioether metabolites of MDA and MAMA inhibit hsert function and simultaneously stimulate dopamine uptake into hsert-expressing SK-N-MC Cells. J. Pharmacol. Exp. Ther. 311, 298-306.
96. Keelan J, O Vergun and MR Duchen (1999) Excitotoxic mitochondrial depolarisation requires both calcium and nitric oxide in rat hippocampal neurons. J. Physiol. 520, 797-813.
97. Kiyatkin EA (2004) Brain hyperthermia during physiological and pathological conditions: Causes, mechanisms, and functional implications. Curr. Neurovasc. Res. 1, 77-90.
98. Klemm HP, HG Baumgarten and HG Schlossberger (1980) Polarographic measurements of spontaneous and mitochondriapromoted oxidation of 5,6- and 5,7-dihydroxytryptamine. J. Neurochem. 35, 1400-1408.
99. Kraemer T and HH Maurer (2002) Toxicokinetics of amphetamines, metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N -alkyl derivatives. Ther. Drug Monit. 24, 277-289. Review.
100. Ladenheim B, IN Krasnova, X Deng, JM Oyler, A Polettini, TH Moran, MA Huestis and JL Cadet (2000) Methamphetamineinduced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol. Pharmacol. 58, 1247-1256.
101. LaVoie MJ, JP Card and TG Hastings (2004) Microglial activation precedes dopamine terminal pathology in methamphetamineinduced neurotoxicity. Exp. Neurol. 187, 47-57.
102. Lee YW, KW Son, G Flora, B Hennig, A Nath and M Toborek (2002) Methamphetamine activates DNA binding of specific redox-responsive transcription factors in mouse brain. J. Neurosci. Res. 70, 82-89.
103. Lin LY, EW Di Stefano, DA Schmitz, L Hsu, SW Ellis, MS Lennard, GT Tucker and AK Cho (1997) Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. DrugMetab. Dispos. 25, 1059-1064.
104. Lotharius J and P Brundin (2002) Pathogenesis of Parkinson's disease, dopamine, vesicles and ?-synuclein. Nat. Rev. Neurosci. 3, 932-942. Review.
105. Luellen BA, DB Miller, AC Chisnell, DL Murphy, JP O'Callaghan and AM Andrews (2003) Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin, 1-methyl-4-(2′-amino-phenyl)-1,2,3,6-tetrahydropyridine. J. Pharmacol. Exp. Ther. 307, 923-931.
106. McCann U, G Hatzidimitriou, A Ridenour, C Fischer, J Yuan, J Katz and G Ricaurte (1994a) Dexfenfluramine and serotonin neurotoxicity, further preclinical evidence that clinical caution is indicated. J. Pharmacol. Exp. Ther. 269, 792-798.
107. McCann UD, A Ridenour, Y Shaham and GA Ricaurte (1994b) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymetham-phetamine (MDMA; "Ecstasy"), a controlled study in humans. Neuropsychopharmacology 10, 129-138.
108. McCann UD, V Eligulashvili and GA Ricaurte (1998) Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 1087-11102.
109. MacMicking J, QW Xie and C Nathan (1997) Nitric oxide and macrophage function. Annu. Rev. Immunol. 15, 323-350. Review.
110. Mennini T, C Fracasso, A Cagnotto, A Bergami, E Frittoli, M Gobbi, S Caccia and S Garattini (1996) In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat. Naunyn Schmiedebergs Arch. Pharmacol. 353, 641-647.
111. Miller DB and JP O'Callaghan (1995) The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol. Neurobiol. 11, 177-192.
112. Miller DB and JP O'Callaghan. (2003) Elevated environmental temperature and methamphetamine neurotoxicity. Environ. Res. 92, 48-53.
113. Miller RT, SS Lau and TJ Monks (1997) 2,5-Bis-(glutathion-S-yl)-α-methyl-dopamine, a putative metabolite of (+/-)-3,4-methyl-enedioxyamphetamine, decreases brain serotonin concentrations. Eur. J. Pharmacol. 323, 173-180.
114. Mills EM, DE Rusyniak and JE Sprague (2004) The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J. Mol. Med., in press.
115. Molliver ME, UV Berger, LA Mamounas, DC Molliver, E O'Hearn and MA Wilson (1990) Neurotoxicity of MDMA and related compounds, anatomic studies. Ann. NYAcad. Sci. 600, 649-661.
116. Monks TJ and DC Jones (2003) Metabolism and toxicity of quinones, quinonimines, quinone methides, and quinonethioethers. Curr. Drug Metab. 3, 425-438. Review.
117. Monks TJ and SS Lau (1997) Biological reactivity of polyphenolicglutathione conjugates. Chem. Res. Toxicol. 10, 1296-1313. Review.
118. Monks TJ and SS Lau (1998) The pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu. Rev. Pharmacol. Toxicol. 38, 229-255. Review.
119. Monks TJ, DC Jones, F Bai and SS Lau (2004) The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther. Drug Monit. 26, 132-136.
120. Nash JF and BK Yamamoto (1992) Methamphetamine neurotoxicity and striatal glutamate release, comparison to 3,4-methylene-dioxymethamphetamine. Brain Res. 581, 237-243.
121. Nixdorf WL, KB Burrows, GA Gudelsky and BK Yamamoto (2001) Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J. Neurochem. 77, 647-654.
122. Nobin A, HG Baumgarten, A Björklund, L Lachenmayer and U Stenevi (1973) Axonal degeneration and regeneration of bul-bospinal indolamine neurons after 5,6-dihydroxytryptamine treatment. Brain Res. 56, 1-24.
123. O'Callaghan JP and DB Miller (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741-751.
124. O'Callaghan JP and DB Miller (2001) Neurotoxic effects of substituted amphetamines in rats and mice, In Handbook of Neurotoxicology, Vol. 2 (Masssaro EJ, Ed.) (Humana Press: Totowa NJ), pp 269-301.
125. Orio L, E O'Shea, V Sanchez, JM Pradillo, I Escobedo, J Camarero, MA Moro, AR Green and MI Colado (2004) 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain, studies on the relationship with acute hyperthermia and 5-HT depletion. J. Neurochem. 89, 1445-1453.
126. Peng W and R Simantov (2003) Altered gene expression in frontal cortex and midbrain of 3,4-methylenedioxymethamphetamine (MDMA) treated mice, differential regulation of GABA transporter subtypes. J. Neurosci. Res. 72, 250-258.
127. Pisani A, P Gubellini, P Bonsi, F Conquet, B Picconi, D Centonze, G Bernardi and P Calabresi (2001) Metabotropic glutamate receptor 5 mediates the potentiation of N -methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106, 579-587.
128. Ricaurte GA, LE DeLanney, I Irwin and JW Langston (1988) Toxic effects of MDMA on central serotonergic neurons in the primate, importance of route and frequency of drug administration. Brain Res. 446, 165-168.
129. Ricaurte GA, J Yuan and UD McCann (2000a) (+/ -)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity, studies in animals. Neuropsychobiology 42, 5-10. Review.
130. Ricaurte GA, UD McCann, Z Szabo and U Scheffel (2000b) Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol. Lett. 112-113, 143-146. Review.
131. Rocher C and AM Gardier (2001) Effects of repeated systemic administration of d-fenfluramine on serotonin and glutamate release in rat ventral hippocampus, comparison with methamphetamine using in vivo microdialysis. Naunyn Schmiedebergs Arch. Pharmacol. 363, 422-428.
132. Rosengren E, E Linder-Eliasson and A Carlsson (1985) Detection of 5-S-cysteinyl-dopamine in human brain. J. Neural Transm. 63, 247-253.
133. Rothman RB and MH Baumann (2000) Neurochemical mechanisms of phentermine and fenfluramine, therapeutic and adverse effects. DrugDev. Res. 51, 52-65.
134. Rothman RB, MH Baumann, CM Dersch, DV Romero, KC Rice, FI Carroll and JS Partilla (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 39, 32-41.
135. Rothman RB, S Jayanthi, X Wang, CM Dersch, JL Cadet, T Prisinzano, KC Rice and MH Baumann (2003) High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse 50, 233-239.
136. Rudnick G and SC Wall (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)], serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. USA 89, 1817-1821.
137. Sabol KE, JB Richards and LS Seiden (1992) The NMDA receptor antagonist MK-801 does not protect against serotonin depletions caused by high doses of DL-fenfluramine. Brain Res. 582, 129-133.
138. Salzmann J, C Marie-Claire, S Le Guen, BP Roques and F Noble (2003) Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice. Br. J. Pharmacol. 140, 831-838.
139. Sanchez V, M Zeini, J Camarero, E O'Shea, L Bosca, AR Green and MI Colado (2003) The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immuno-reactivity induced by methamphetamine in the mouse striatum. J. Neurochem. 85, 515-524.
140. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240, 1-7.
141. Schmidt CJ (1994) Neurochemistry of ring-substituted amphetamine analogs, In: Amphetamine and its Analogs (Cho AK and DS Segal (Eds.) (Academic Press: San Diego, New York), pp 151-176.
142. Schmidt CJ, L Wu and W Lovenberg (1986) Methylenedioxymethamphetamine, a potentially neurotoxic amphetamine analogue. Eur. J. Pharmacol. 124, 175-178.
143. Schmued LC (2003) Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res. 974, 127-133.
144. Schmued L, W Slikker Jr, P Clausing and J Bowyer (1999) d-Fenfluramine produces neuronal degeneration in localized regions of the cortex, thalamus, and cerebellum of the rat. Toxicol. Sci. 48, 100-106.
145. Segura M, J Ortuno, M Farre, JA McLure, M Pujadas, N Pizarro, A Llebaria, J Joglar, PN Roset, J Segura and R de La Torre (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem. Res. Toxicol. 14, 1203-1208.
146. Segura M, J Ortuno, JA McLure, M Pujadas, N Pizarro, M Farre, A Llebaria, J Joglar, J Segura and R de la Torre (2002) High-performance liquid chromatography with electrochemical detection applied to the analysis of 3,4-dihydroxymethamphetamine in human plasma and urine. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 769, 313-321.
147. Seiden LS and G Vosmer (1984) Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol. Biochem. Behav. 21, 29-31.
148. Shankaran M, BK Yamamoto and GA Gudelsky (2001) Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 40, 55-64.
149. Siman R, TK McIntosh, KM Soltesz, Z Chen, RW Neumar and VL Roberts (2004) Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol. Dis. 16, 311-320.
150. Simantov R and W Peng (2004) MDMA (Ecstasy) controls in concert a group of genes involved in GABA neurotransmission. FEBS Lett. 563, 3-6.
151. Sinhababu AK and RT Borchardt (1985) Mechanism and products of autoxidation of 5,7-dihydroxytryptamine. J. Am. Chem. Soc. 107, 7618-7627.
152. Sotelo C (1991) Immunohistochemical study of short- and longterm effects of DL-fenfluramine on the serotonergic innervation of the rat hippocampal formation. Brain Res. 541, 309-326.
153. Spencer JP, Whiteman M, Jenner P and B Halliwell (2002) 5-S-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J. Neurochem. 81, 122-129.
154. 3 -adrenoreceptor antagonists. Br. J. Pharmacol. 142, 667-670.
155. Sprague JE, NM Mallett, DE Rusyniak and E Mills (2004b) UCP3 and thyroid hormone involvement in methamphetamine-induced hyperthermia. Biochem. Pharmacol. 68, 1339-1343.
156. Stewart CW, JF Bowyer and W Slikker Jr (1997) Elevated environmental temperatures can induce hyperthermia during d-fenfluramine exposure and enhance 5-hydroxytryptamine (5-HT) depletion in the brain. J. Pharmacol. Exp. Ther. 283, 1144-1150.
157. Stewart VC, MA Sharpe, JB Clark and SJ Heales (2000) Astrocyte-derived nitric oxide causes both reversible and irreversible damage to the neuronal mitochondrial respiratory chain. J. Neurochem. 75, 694-700.
158. Streit WJ, T Morioka and AN Kalehua (1992) MK-801 prevents microglial reaction in rat hippocampus after forebrain ischemia. Neuroreport 3, 146-148.
159. Tabatabaie T and G Dryhurst (1998) Molecular mechanisms of action of 5,6- and 5,7-dihydroxytryptamine, In: Highly Selective Neurotoxins (Kostrzewa RM, Ed.) (Humana Press: Totowa NJ), pp 269-291.
160. Thiriet N, B Ladenheim, MT McCoy and JL Cadet (2002) Analysis of ecstasy (MDMA) -induced transcriptional responses in the rat cortex. FASEB J 16, 1887-1894.
161. Thoenen H and JP Tranzer (1968) Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn Schmiedebergs Arch. Pharmacol. Exp. Pathol. 261, 271-288.
162. Thoenen H and JP Tranzer (1973) The pharmacology of 6-hydroxydopamine. Annu. Rev. Pharmacol. 113, 169-80. Review.
163. Thomas DM, PD Walker, JA Benjamins, TJ Geddes and DM Kuhn (2004a) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 311, 1-7 (published online May 26, 2004).
164. Thomas DM, DM Francescutti-Verbeem, X Liu and DM Kuhn (2004b) Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment - an oligonucleotide microarray approach. J. Neurochem. 88, 380-393.
165. Thomas DM, J Dowgiert, TJ Geddes, D Francescutti-Verbeem, X Liu and DM Kuhn (2004c) Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 367, 349-354.
166. Tor-Agbidye J, B Yamamoto and JF Bowyer (2001) Seizure activity and hyperthermia potentiate the increases in dopamine and serotonin extracellular levels in the amygdala during exposure to d-amphetamine. Toxicol. Sci. 60, 103-111.
167. Ugolini A, M Corsi and F Bordi (1999) Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 38, 1569-1576.
168. Vatassery GT (1996) Oxidation of vitamin E, vitamin C, and thiols in rat brain synaptosomes by peroxynitrite. Biochem. Pharmacol. 52, 579-586.
169. Vatassery GT, JC Lai, EG DeMaster, WE Smith and HT Quach (2004) Oxidation of vitamin E and vitamin C and inhibition of brain mitochondrial oxidative phosphorylation by peroxynitrite. J. Neurosci. Res. 75, 845-853.
170. Vollenweider FX, RT Jones and MJ Baggott (2001) Caveat emptor, editors beware. Neuropsychopharmacology 24, 461-463.
171. Wang JQ, L Mao, NK Parelkar, Q Tang, Z Liu, S Sarwar and ES Choe (2003) Glutamate-regulated behavior, transmitter release, gene expression and addictive plasticity in the striatum, roles of metabotropic glutamate receptors. Curr. Neuropharmacol. 1, 1-20.
172. Wang X, MH Baumann, H Xu and RB Rothman (2004) 3,4-meth-ylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter pro tein and glial fibrillary acidic protein. Synapse 53, 240-248.
173. Wiklund L and A Björklund (1980) Mechanisms of regrowth in the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. II. Fluorescence histochemical observations. Brain Res. 191, 129-160.
174. Wrona MZ and G Dryhurst (1998) Oxidation of serotonin by superoxide radical: Implications to neurodegenerative brain disorders. Chem. Res. Toxicol. 11, 639-650.
175. Wrona MZ, Yang Z, McAdams M, O'Connor-Coates S and G Dryhurst (1995a) Hydroxyl radical-mediated oxidation of serotonin: Potential insights into the neurotoxicity of methamphetamine. J. Neurochem. 64, 1390-1400.
176. Wrona, MZ, S Singh and G Dryhurst (1995b) Influence of glu tathione on the electrochemical and enzymatic oxidation of serotonin. J. Electroanalyt. Chem. 362, 41-51.
177. Yeh SY (1999) N -tert-butyl-?-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. Synapse 31, 169-177.
178. Zaczek R, G Battaglia, S Culp, NM Appel, JF Contrera and EB De Souza (1990) Effects of repeated fenfluramine administration on indices of monoamine function in rat brain, pharmacokinetic, dose response, regional specificity and time course data. J. Pharmacol. Exp. Ther. 253, 104-112.
179. Zheng Y and R Laverty (1998) Role of brain nitric oxide in (+/-)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. Brain Res. 795, 257-263.